Laboratory and clinical studies on ceftriaxone (Ro 13-9904)

Kikuo Onuma, Seiichi Aonuma, Akira Watanabe, Masako Sasaki, Kotaro Oizumi, Kiyoshi Konno

    Research output: Contribution to journalArticlepeer-review


    The MICs of ceftriaxone (CTRX, Ro 13-9904) against 120 bacterial strains from patients’ sputa were compared with those of cefazolin, cefotiam, cefmetazole and ceftizoxime, and the efficacy of CTRX in the treatment of eight patients with respiratory tract infections (five patients with pneumonia, two with lung abscess and one with acute exacerbation of chronic respiratory tract infection) was evaluated. The results of in vitro tests revealed that CTRX was less active against S. aureus than the above four other antibacterial agents, but was as highly active against E. coli, K. pneumoniae and S. marcescens as ceftizoxime. The antipseudomonal activity of CTRX was minimal. One gram of CTRX per day was given to the patients by an intravenous drip infusion. Clinical response to the treatment with CTRX was excellent in two patients, good in five and fair in one. Two strains of putative causative agents, S. pneumoniae and H. influenzae, in two patients were eradicated. In six of these eight patients, serum transaminase values were elevated during the treatment. Usually they returned to the pre-treatment levels soon after cessation of the drugs. No other side effects were observed.

    Original languageEnglish
    Pages (from-to)241-244
    Number of pages4
    Issue numberSupplement
    Publication statusPublished - 1984 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'Laboratory and clinical studies on ceftriaxone (Ro 13-9904)'. Together they form a unique fingerprint.

    Cite this